AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin

Roche has detailed Tecentriq’s performance in early-stage liver cancer from a positive phase 3 trial. But a negative sign of patient deaths might raise some eyebrows, and it could force the company to delay a potential FDA filing.